DAWN News and Press, Day One Biopharmaceuticals Inc.

Are DAWN and TALK Obtaining Fair Deals for their Shareholders? PR Newswire Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareh...

2026-03-07 15:15:36 ET More on related tickers, etc. Star Bulk Carriers: Financially Strong But Not Undervalued BlackRock: Paying A Premium For Index-Like Returns The AES Corporation (AES) Stock Analysis: Riding The AI Wave | 2-Minute Analysis AES cut at Morg...

2026-03-06 18:09:06 ET The S&P 500 (SNPINDEX:^GSPC) fell 1.33% to 6,740.02, the Nasdaq Composite (NASDAQINDEX:^IXIC) slid 1.59% to 22,387.68, and the Dow Jones Industrial Average (DJINDICES:^DJI) dropped 0.95% to 47,501.55 as a weak jobs report and surgin...

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - March 6, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Day One Biopharmaceuticals, Inc. ("Day One" or the "Company") (NASDAQ: DAWN) for possible breaches of fiduciary dut...

A look at the top 10 most actives in the United States Decent Holding Inc. (DXST) rose 75.0% to $0.2668 on volume of 572,206,411 shares Peraso Inc. (PRSO) rose 112.7% to $1.725 on volume of 319,448,826 shares Trio Petroleum Corp. (TPET) rose 22.0% to $1.94 on volume of 247,787,710 shares ...

2026-03-06 13:39:37 ET Day One Biopharmaceuticals (NASDAQ: DAWN) ripped higher on Friday morning after Servier signed a definitive agreement to acquire the California-based firm for about $2.5 billion in cash. Servier’s deal rewrites DAWN’s technical profile, valui...

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options a...

2026-03-06 09:07:21 ET More on Day One Biopharmaceuticals Day One Biopharmaceuticals: 'Strong Buy,' Several 2026 Milestones In Play Plus OJEMDA Growth Day One Biopharmaceuticals: Commercial Performance With Catalysts Ahead Day One Biopharmaceuticals, Inc. (DAWN) Q4 2...

Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs Transaction represents total equity value of approximately $2.5 billion SURESNES, France and BRISBANE, Calif., March 0...

2026-03-05 14:41:06 ET The last time I spoke about Day One Biopharmaceuticals ( DAWN ), it was regarding a Seeking Alpha article entitled " Day One Biopharmaceuticals: Mersana Acquisition Ignites March Towards Unmet Need ." I noted that this company had completed its acquisition o...